Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adverum Biotechnologies, Inc.ADVM · Entity 71889 | Director | May 12, 2021 | May 14, 2021 |
| Aligos Therapeutics, Inc.ALGS · Entity 7352 | Director | June 23, 2022 | June 27, 2022 |
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | June 15, 2018 | June 16, 2018 |
| Gritstone bio, Inc.GRTS · Entity 80946 | Director | August 25, 2021 | August 27, 2021 |
| Passage BIO, Inc.PASG · Entity 7829 | Director · 10% owner | May 25, 2023 | May 26, 2023 |
| Tempest Therapeutics, Inc.TPST · Entity 7734 | Director | June 17, 2022 | June 22, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adverum Biotechnologies, Inc.
Report date May 12, 2021 · Filed May 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.70 · Expires 2031-05-11 | Direct | 40,000 |
Reported balance
After 2021-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-12 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares subject to the option will vest on the earlier of May 12, 2022 or the 2022 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of May 12, 2022 or the 2022 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date.
Aligos Therapeutics, Inc.
Report date June 23, 2022 · Filed June 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2032-06-23 | Direct | 15,000 |
Reported balance
After 2022-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-23 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2023 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2023 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.
CRISPR Therapeutics AG
Report date June 15, 2018 · Filed June 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.31 · Expires 2028-06-15 | IndirectSee Footnotes | 30,000 |
Reported balance
After 2018-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-15 · Grant · Acquired 30,000 · Balance 30,000 F2: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Bradley Bolzon, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Bolzon. Each of the Reporting Person and Mr. Bolzon are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3: (Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F1: This option was granted on June 15, 2018 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 15, 2018 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018.
F2: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Bradley Bolzon, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Bolzon. Each of the Reporting Person and Mr. Bolzon are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC.
F3: (Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Gritstone bio, Inc.
Report date August 25, 2021 · Filed August 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 902,965 |
Reported balance
After 2021-08-25 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-08-25 · Other · Disposed 444,744 · Balance 902,965 F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("VV I") to its partners pursuant to a Rule 10b5-1 trading plan. F2: Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP, and the Reporting Person disclaims beneficial ownership of the shares held by VVI, except to the extent of their respective pecuniary interests therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,668 |
Reported balance
After 2021-08-25 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2021-08-25 · Other · Acquired 6,668 · Balance 6,668 F3: Represents a change in the form of ownership of VV I GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV I. F4: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2021-08-25 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2021-08-25 · Other · Disposed 6,668 · Balance 0 F5: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP, to its partners. F4: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,612 |
Reported balance
After 2021-08-25 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2021-08-25 · Other · Acquired 6,612 · Balance 6,612 F6: Represents a change in the form of ownership of VV I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV I GP. F7: Shares held by VV I GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2021-08-25 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2021-08-25 · Other · Disposed 6,612 · Balance 0 F8: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP-GP, to its members. F7: Shares held by VV I GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,723,031 |
Reported balance
Holding disclosure · report date 2021-08-25 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 2,723,031 F10: Shares held by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 81,908 |
Reported balance
Holding disclosure · report date 2021-08-25 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 81,908 F11: Shares held by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 90,756 |
Reported balance
Holding disclosure · report date 2021-08-25 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 90,756 F12: Shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). VV V is the sole general partner of VOAF I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 207,234 |
Reported balance
Holding disclosure · report date 2021-08-25 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 207,234 F13: Shares held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein, if any. |
| Common StockSEC Table I · non-derivative | Direct | 128 |
Reported balance
After 2021-08-25 transaction · row 6
1 source rowRow 6 · 2021-08-25 · Other · Acquired 128 · Balance 128 F9: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV I GP-GP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("VV I") to its partners pursuant to a Rule 10b5-1 trading plan.
F2: Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP, and the Reporting Person disclaims beneficial ownership of the shares held by VVI, except to the extent of their respective pecuniary interests therein, if any.
F3: Represents a change in the form of ownership of VV I GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV I.
F4: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein, if any.
F5: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP, to its partners.
F6: Represents a change in the form of ownership of VV I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV I GP.
F7: Shares held by VV I GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
F8: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP-GP, to its members.
F9: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV I GP-GP.
F10: Shares held by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein, if any.
F11: Shares held by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein, if any.
F12: Shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). VV V is the sole general partner of VOAF I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein, if any.
F13: Shares held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein, if any.
Passage BIO, Inc.
Report date May 25, 2023 · Filed May 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2033-05-24 | Direct | 24,000 |
Reported balance
After 2023-05-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-25 · Grant · Acquired 24,000 · Balance 24,000 F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2024 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2024 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.
Tempest Therapeutics, Inc.
Report date June 17, 2022 · Filed June 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2032-06-16 | Direct | 3,500 |
Reported balance
After 2022-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-17 · Grant · Acquired 3,500 · Balance 3,500 F1: Vests over one (1) year, with one hundred per cent (100%) of the award vesting on the first anniversary of the date of grant subject to the reporting person's continuous service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests over one (1) year, with one hundred per cent (100%) of the award vesting on the first anniversary of the date of grant subject to the reporting person's continuous service through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 66,490 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 13 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 66,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F6 · ownership.nature: These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Stock | 60,219 | $14.00 | $843,066.00 |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 12 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,443,803 F5 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 173,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 11 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,383,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F5 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 2,210,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 10 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,210,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F5 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Stock | 602 | $14.00 | $8,428.00 |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 9 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 24,334 F4 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 1,454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 8 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 23,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F4 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 19,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 7 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F4 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 2,754 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 6 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F4 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Stock | 95,596 | $14.00 | $1,338,344.00 |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 5 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,104,045 F3 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 231,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 4 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,008,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 3,100,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 3 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,777,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 437,247 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 2 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 676,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 18, 2016 Filed Oct 20, 2016 21:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-16-032066 · doc4.xml · derivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2026-10-18 F1 · derivative.exercise_date: This option was granted on October 18, 2016 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016. Read SEC document |
| October 18, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · derivative · entry 20 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 60,000 Underlying: Common Stock · 30,000 shares Expires 2026-10-18 F9 · shares: The option grant reported hereby was made to Bradley Bolzon as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person (the grant of which was previously reported by the Reporting Person) and one-half of the reported securities are held by Mr. Bolzon. Pursuant to the agreements described in footnote (1), the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F10 · derivative.exercise_date: This option was granted on October 18, 2016 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016. F9 · derivative.underlying_shares: The option grant reported hereby was made to Bradley Bolzon as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person (the grant of which was previously reported by the Reporting Person) and one-half of the reported securities are held by Mr. Bolzon. Pursuant to the agreements described in footnote (1), the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F9 · balance_after: The option grant reported hereby was made to Bradley Bolzon as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person (the grant of which was previously reported by the Reporting Person) and one-half of the reported securities are held by Mr. Bolzon. Pursuant to the agreements described in footnote (1), the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F9 · ownership.nature: The option grant reported hereby was made to Bradley Bolzon as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person (the grant of which was previously reported by the Reporting Person) and one-half of the reported securities are held by Mr. Bolzon. Pursuant to the agreements described in footnote (1), the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.